Posted by Michael Wonder on 25 Apr 2019
FDA approves Bausch Health's Duobrii (halobetasol propionate and tazarotene) lotion 0.01%/0.045% for plaque psoriasis in adults
25 April 2019 - First and only topical lotion combining halobetasol propionate and tazarotene in one formulation.
Bausch Health and its dermatology business, Ortho Dermatologics announced today that the U.S. FDA has approved the new drug application for Duobrii (halobetasol propionate and tazarotene) lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults.
Duobrii is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. In a year-long safety study, patients used Duobrii lotion for up to 24 weeks of continuous use and up to 52 weeks of as-needed use. Duobrii is expected to be available in June 2019.
